Article

Fred R. Hirsch Discusses His Own Cancer Diagnosis

Author(s):

Fred R. Hirsch, MD

Fred R. Hirsch, from the University of Colorado and IASLC, discusses some of the unique challenges he faced as a patient.

Fred R. Hirsch, professor of medicine, professor in pathology, University of Colorado, CEO, International Associate for the Study of Lung Cancer (IASLC), discusses some of the unique challenges he faced as a patient.

When Hirsch was diagnosed with lymphoma, he had been practicing medical oncology for 20 years. Before that moment, Hirsch admits, he thought he knew everything about cancer and cancer treatment. Then, new perspectives came flooding in.

Related Videos
Image of man with black hair.
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Related Content
Image of water bottle, weights, and apple.
February 22nd 2025

Debunking the Myth That Healthy People Don’t Get Cancer

Jacey Tramutt Amy Schneidmiller-Johnston
The myth that "healthy people don’t get cancer" contributed to my shame, but I’ve learned that cancer can affect anyone, regardless of lifestyle choices.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Dr. Robert Jones is a professor of Clinical Cancer Research at The University of Glasgow School of Cancer Sciences, in Scotland.
February 15th 2025

Bavencio Has Efficacy in The Real-World Treatment of Urothelial Cancer

Dr. Robert Jones
Following treatment with Bavencio, patients with urothelial cancer lived for 17 months and their cancer remained stable for nine months.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
FDA approves Adcetris plus Revlimid and Rituxan relapsed or refractory large B-cell lymphoma.
February 12th 2025

FDA Approves Adcetris With Revlimid and Rituxan For R/R LBCL

Alex Biese
The FDA has approved Adcetris plus Revlimid and Rituxan in adults with relapsed or refractory large B-cell lymphoma.
Dr. Tycel Phillips discusses the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL. | © Digilife - stock.adobe.com
February 11th 2025

FDA Approval of Calquence Combo Brings Optimism in MCL

Ryan Scott
Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL.